Program
Pioglitazone
Also written as “pioglitazone”, “Pioglitazone 30 mg” and “Pioglitazone and azilsartan”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Alzheimer Disease · Fatty Liver · Peripheral Arterial Disease, led by 10 companies.
Drug pagePioglitazone: every studyMany companies study it; this page follows only the 52 they lead. All 336 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 330 open or running | phase 4since Jun 27, 2007 | Sep 9, 2005 | none ahead |
| Boryung Pharmaceuticalits history only | 42 open or running | phase 3since May 9, 2021 | May 9, 2021 | none ahead |
| Merckits history only | 40 open or running | phase 3since Jul 22, 2008 | Aug 2, 2007 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 4since Apr 2, 2009 | Dec 22, 2005 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 4since Oct 16, 2007 | Oct 16, 2007 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Dr. Muhammad Abdulghaniits history only | 10 open or running | no phasesince Aug 16, 2016 | Aug 16, 2016 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Jul 19, 2021 | Jul 19, 2021 | none ahead |
| Medtronicits history only | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Strekinits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
Also a collaborator on its studies: Parexel, Zinfandel Pharmaceuticals, Eli Lilly and Takeda Pharmaceuticals North America.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Sep 9, 2005.
- Jul 24, 2008Phase 2 study in Diabetes MellitusNCT00722917 · 323 enrolled · United States
- Jul 30, 2008Phase 3 study in Diabetes MellitusNCT00727857 · 600 enrolled · United States, Chile, Mexico and more
- Sep 17, 2008Phase 4 study in Diabetes MellitusNCT00754403 · 312 enrolled
- Sep 26, 2008Phase 2 study in Diabetes MellitusNCT00762736 · 704 enrolled · United States, Argentina, Chile and more
- Oct 8, 20083 phase 3 studies in Diabetes MellitusNCT00772174, NCT00770952, NCT00770653
- Oct 8, 20082 phase 4 studies in Diabetes MellitusNCT00770835, NCT00770445
- Oct 9, 20084 phase 2 studiesNCT00771004, NCT00770640, NCT00770575 and 1 more
- May 13, 2010Phase 3 study in Diabetes Mellitus, Type 2NCT01124656 · 26 enrolled
- Feb 1, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01289119 · 506 enrolled · China, Hong Kong, Taiwan
- Oct 18, 2011Phase 1 study in HealthyNCT01456117 · 61 enrolled · United States
- Aug 31, 2012Phase 4 study in Diabetes MellitusNCT01686711 · 207 enrolled · Japan
- Aug 26, 2013Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseNCT01931566 · 3,494 enrolled · United States, Australia, Germany and more
- Oct 24, 2013Phase 4 study in Diabetes Mellitus, Type 2NCT01972724 · 114 enrolled · Korea, Republic of
- Nov 4, 2014Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseNCT02284906 · 40 enrolled · United States, Australia, Switzerland and more
TargetBeta
“Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule
Other programs on PPARG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| saroglitazarrule | Zydus Lifesciences | phase 4 | 19 |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
| T3D-959rule | t3d-therapeutics-inc | phase 3 | 3 |
Studies
All 33 Takeda leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02284906Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Switzerland and more | 3 | Terminated | Jan 31, 2018 | 40 |
| NCT01972724Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | Oct 17, 2016 | 114 |
| NCT01931566Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Germany and more | 3 | Terminated | Jul 24, 2018 | 3,494 |
| NCT01686711Diabetes Mellitus · Japan | 4 | Completed | Dec 2013 | 207 |
| NCT01456117Healthy · United States | 1 | Completed | Jul 2012 | 61 |
| NCT01289119Diabetes Mellitus, Type 2 · China, Hong Kong, Taiwan | 3 | Completed | Dec 2011 | 506 |
| NCT01124656Diabetes Mellitus, Type 2 | 3 | Terminated | May 2007 | 26 |
| NCT00771004Coronary Artery Disease · Germany | 2 | Completed | Feb 2009 | 63 |
| NCT00770952Diabetes Mellitus · Germany | 3 | Completed | Dec 2008 | 91 |
| NCT00770653Diabetes Mellitus · Germany | 3 | Completed | May 2009 | 305 |
| NCT00770640Diabetes Mellitus · Germany | 2 | Completed | Jun 2010 | 40 |
| NCT00770575Cardiovascular Diseases | 2 | Completed | Oct 2006 | 148 |
| NCT00770497Inflammation · Germany | 2 | Completed | May 2008 | 172 |
| NCT00770445Diabetes Mellitus · Germany | 4 | Completed | Jul 2010 | 121 |
| NCT00772174Diabetes Mellitus | 3 | Completed | Feb 2008 | 418 |
| NCT00770835Diabetes Mellitus · Italy | 4 | Completed | May 2011 | 39 |
| NCT00762736Diabetes Mellitus · United States, Argentina, Chile and more | 2 | Completed | Oct 2005 | 704 |
| NCT00754403Diabetes Mellitus | 4 | Completed | Oct 2006 | 312 |
| NCT00727857Diabetes Mellitus · United States, Chile, Mexico and more | 3 | Completed | Aug 2008 | 600 |
| NCT00722917Diabetes Mellitus · United States | 2 | Terminated | Apr 2009 | 323 |
| NCT00708175Glucose Metabolism Disorders · United States | 4 | Completed | Jan 2011 | 156 |
| NCT00676260Diabetes Mellitus · United Kingdom | 2 | Completed | Aug 2004 | 29 |
| NCT00672919Diabetes Mellitus · United States, Puerto Rico | 4 | Completed | Aug 2004 | 305 |
| NCT00521820Diabetes Mellitus | 3 | Terminated | Oct 2003 | 518 |
| NCT00521742Diabetes Mellitus | 3 | Completed | Jan 2003 | 300 |
| NCT00494312Diabetes Mellitus | 4 | Completed | Jun 2005 | 2,120 |
| NCT00395512Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Feb 2008 | 655 |
| NCT00376181Diabetes Mellitus, Type 2 · United States, Argentina, Chile and more | 3 | Terminated | May 2007 | 96 |
| NCT00331487Diabetes Mellitus · United States | 3 | Completed | Mar 2004 | 719 |
| NCT00328627Diabetes Mellitus, Type 2 · United States, Australia, Brazil and more | 3 | Completed | Mar 2008 | 1,554 |
| NCT00225277Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Oct 2007 | 547 |
| NCT00225264Diabetes Mellitus · United States | 3 | Completed | May 2006 | 458 |
| NCT00174993Diabetes Mellitus · Austria, Belgium, Czech Republic and more | 3 | Completed | Jan 2005 | 4,373 |
How it is read
Names in the registry
- “Pioglitazone”, 33 entries
- “pioglitazone”, 5 entries
- “Pioglitazone 30 mg”, 4 entries
- “Pioglitazone and azilsartan”, 4 entries
- “TAK-379”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 42 studies
- Diabetes Mellitus, 4 studies
- Alzheimer Disease, 2 studies
- Fatty Liver, 1 study
- Peripheral Arterial Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.